BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21787123)

  • 1. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models.
    Al-Aridi C; Abboud MR; Saab R; Eid D; Jeha S; Chan AK; Muwakkit SA
    Pediatr Hematol Oncol; 2011 Nov; 28(8):676-81. PubMed ID: 21787123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
    Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
    Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.
    Zuurbier SM; Lauw MN; Coutinho JM; Majoie CB; van der Holt B; Cornelissen JJ; Middeldorp S; Biemond BJ; Stam J
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1679-84. PubMed ID: 25934140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
    Nowak-Göttl U; Kenet G; Mitchell LG
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):103-14. PubMed ID: 19285277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon.
    Muwakkit S; Al-Aridi C; Samra A; Saab R; Mahfouz RA; Farra C; Jeha S; Abboud MR
    Am J Hematol; 2012 Jul; 87(7):678-83. PubMed ID: 22565284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
    Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
    Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
    Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol.
    Sutor AH; Mall V; Thomas KB
    Klin Padiatr; 1999; 211(4):201-4. PubMed ID: 10472550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
    Giordano P; Molinari AC; Del Vecchio GC; Saracco P; Russo G; Altomare M; Perutelli P; Crescenzio N; Santoro N; Marchetti M; De Mattia D; Falanga A
    Am J Hematol; 2010 May; 85(5):325-30. PubMed ID: 20425794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.
    Santoro N; Colombini A; Silvestri D; Grassi M; Giordano P; Parasole R; Barisone E; Caruso R; Conter V; Valsecchi MG; Masera G; Rizzari C
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):348-55. PubMed ID: 23619106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
    Lee JH; Lee J; Yhim HY; Oh D; Bang SM
    J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
    Goyal G; Bhatt VR
    Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
    Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
    Baillargeon J; Langevin AM; Lewis M; Thomas PJ; Mullins J; Dugan J; Pollock BH
    Cancer; 2005 Dec; 104(12):2858-61. PubMed ID: 16288492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol.
    Kirschke R; Nürnberger W; Eckhof-Donovan S; Nürnberger I; Göbel U
    Klin Padiatr; 1998; 210(4):285-90. PubMed ID: 9743967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.